N Mikhaeel-Kamel

Learn More
Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains < 1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary(More)
Lung cancer is the leading cause of cancer deaths for both men and women in the United States. Most patients present with late stages of disease, rendering them incurable. Despite this dismal outcome, there is optimism; modern treatment for lung cancer has been shown to increase survival, improve quality of life, and be cost effective. This article reviews(More)
  • 1